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Health-Seeking Behavior and Out-of-Pocket Expenditure
in Patients with Visceral Leishmaniasis in Nepal
T. Shrestha
NGO, Kathmandu, Nepal
Leishmaniasis is endemic in 88 countries and 350 million
people are at risk for acquiring one or the other form of leish-
maniasis with an overall prevalence of 12 million worldwide.
The visceral type, visceral leishmaniasis (VL) or kala-azar
was known to be endemic in Southern Terai (plain region) of
Nepal since 1953. Approximately 5.5 million inhabitants are
estimated to be at risk of VL in Nepal at present.
We conducted a study to investigate the health seek-
ing behavior and out-of-pocket expenditure for health in
patients with VL in Nepal. A sample of VL patients was inter-
viewed at B.P. Koirala Institute of Health Sciences (BPKIHS),
a hospital located within the endemic region for Kala-azar
in Nepal.
Between September and November 2004 one hundred
sixty patients were conﬁrmed with a diagnosis of Kala-azar
at BPKIHS. Out of these, 60 [37.5 per cent of 160] patients
were enrolled for the study; among them 52 per cent were
males. Age of the study population ranged between 18 to 75
yrs, with mean age of 32.3 yrs (SD± 15.1).
Almost half of the patients delayed seeking care for VL
for more than 100 days. In addition, the factors playing a
signiﬁcant role in making delayed health seeking were found
as gender, perception of disease and the stigma attached.
The study got evidence that the severity of the disease and
its immediate economic and social impacts determines the
decision making regarding the health seeking behavior more
than knowledge about the disease.
Almost all of the patients (95 per cent) had visited tra-
ditional healers followed by private health care providers
[46.7 per cent] for treatment of illness. Their visit to gov-
ernment health care providers and referral center is either
fourth or ﬁfth which explains delays in the adequate man-
agement of the patient.
The out of pocket expenditure of the patient is maximum
in the treatment of kala-azar. The mean total expenditure
in VL is 105 US$. An average of 100 days of working days
(maximum 210 days and minimum 14 days) was lost due to
the disease.
The ﬁndings of the study reﬂects on the advocacy, sensi-
tization and develop skill of protection and control measures
to the individuals. The advocacy/awareness intervention is
most essential part to reduce the kala-azar morbidity and
mortality.
Some major interventions are recommended in this study
to reduce morbidity and mortality of VL is given below.
Advocacy, orientation and health education should be
provided regarding Kala-azar disease, its transmission, and
preventive & control measures to family level, child and
youth group, mothers groups and school students as well
as community level. It should be in multi disciplinary
approach. Educational programs focused on reducing stigma
and increasing control over the resources of females and
decision making process in health seeking behaviors of VL
and to be conducted in formal and informal settings.
As there is a strong stigma regarding the traditional
healers in the population, the use of traditional healers
for health education and development of awareness of the
disease can be implicated. Training and orientation to tra-
ditional healers on modern treatment systems should be
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Background: Leishmaniasis, caused by an intracellular
protozoan parasite, Leishmania major which is transmit-
ted through the bite of sand ﬂies. The disease is prevalent
in many parts of the world. TSA is the immuno-dominant
antigen of Leishmania major which is considered as the
most promising molecule for a recombinant or DNA vaccine
against leishmaniasis.
Materials and Methods: In the present study, we evalu-
ated TSA - encoded DNA vaccine against Leishmania major in
BALB/c mice. The ﬁrst was done the genomic DNA extraction
and then, done PCR ampliﬁcation and recombinant plasmid
construction and tranfection of recombinant pcTSA into the
eukaryotic cells and then done SDS-PAGE and Western blot
analysis. The mice were grouped to be based on administra-
tion content as follows: 1-PBS (as control group), 2-pcDNA3
(as control group), 3-pcTSA (as vaccinated group) (100g of
pcTSA).
The mice were immunized via intramuscular (i.m.)into
both quadricepses with 100L of administration con-
tent according to their grouping. Three inoculations were
employed at two weeks interval. Three weeks after the
last immunization, mice of each groups (vaccinated and
unvaccinated mice) were challenged at the base of tail
by the intradermal (i.d.) route with 2× 106 Leishmania
major promastigotes (Strain MRHO/IR/75/ER). The measur-
ing of the diameter of lesion at the site of inoculation
was monitored weekly by a Vernier caliper thereafter. Also
the measuring of the weight was monitored weekly by a
scale. All groups of mice were evaluated for lesion devel-
opment and weight increasing for up to 7 weeks after
challenge with Leishmania major. Then, animals were sacri-
ﬁced and was done determination of parasite burden in their
spleen.
The statistical comparisons between experimental
groups were carried out with an analysis of variance (ANOVA)
13th International Congress on Infectious Diseases Abstracts, Poster Presentations e375
and post hoc Tukey test. Statistical analysis of survival time
was carried out with Kaplan-Meier (Log-Rank) test.
Results: The immunized mice with this DNA vaccine pre-
sented an important reduction in diameter of lesion and
increasing of weight compared to the control mice and was
indicated a signiﬁcant difference between the immunized
group and the control groups (p < 0.05). The survival time of
the immunized mice was signiﬁcantly higher than the con-
trol groups (p < 0.05) after challenge with Leishmania major.
The immunized mice had signiﬁcantly lower parasite load
compared to the control mice (p < 0.05).
Conclusion: The ﬁndings of this study, indicated that
the TSA - encoded DNA vaccine induced protection against
infection with Leishmania major in mice. In this study, we
demonstrated that, the TSA -encoded DNA vaccine may be
an excellent candidate for futher vaccine development.
doi:10.1016/j.ijid.2008.05.991
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HIV-associated Cutaneous Dissemination of Visceral Leish-
maniasis, Despite Negligible Immunodeﬁciency. Failure of
Liposomal Amphotericin B Administration, Followed by
Successful Pentamidine-Paromomycin Administration
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Background: In endemic countries, Kala-Azar (K) acts
as an opportunistic infection, when a deep HIV-related
immunodeﬁciency is present; infrequently, a cutaneous
spread was described. Case report. An atypical episode
of HIV-associated K complicated by a diffuse, aspeciﬁc
macular-papular cutaneous involvement was characterized
by absent epidemiological clues, a prolonged course, and
no response to repeated cycles of liposomal amphotericin
B (lAB), despite a CD4+ lymphocyte count >500 cells/L,
maintained thanks to a concurrent antiretroviral treat-
ment. Despite a negligible immunodeﬁciency, K serology
proved negative.Only a prolonged administration of the
second-line i.v. pentamidine (12 weeks), together with
oral paromomycin (7 weeks), led to a cure of K and its
related skin dissemination, in absence of toxicity and dis-
ease relapses.
Discussion: The differential diagnosis of skin dissem-
ination of K (which may appear as single, multiple, or
disseminated macules, papules, plaques, nodules, ulcers),
enters in a broad spectrum of possible HIV-associated com-
plications, and may be the clue of a missed K, so that
a biopsy with histopathology-culture becomes mandatory,
since serology is not reliable also when immunodeﬁciency
is limited. The ﬁrst-line treatment of HIV-associated K
is debated. Pentavalent antimony compounds were the
mainstay in the past 70 years, but lAB seems effective
and safe, especially when administered in short courses.
Like in our case, failure of AB in treating K was anecdo-
tally documented. In our particular episode, a prolonged
pentamidine-paromomycin treatment became necessary,
after multiple failures of lAB. An effective antiretroviral
therapy may restore the immune function and signiﬁcantly
help anti-protozoal treatment, but it was not the case of
our patient, who was virologically suppressed and reached a
CD4+ count of >500 cells/L before of the cutaneous spread.
Also in the HAART era, clinicians facing patients with a
well controlled HIV disease, should carefully assess a non-
speciﬁc rash, which may enter in differential diagnosis with
an elevated number of infectious, allergo-toxic, and dysre-
active disorders. Randomized clinical trials are needed to
aid selection of therapeutic regimens of K with/without a
concurrent immunodeﬁciency, and with/without cutaneous-
other complications, due to the increased frequency
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Background: Fetal infection by Toxoplasma gondii devel-
ops when non-immune mother becomes infected during
pregnancy. Accurate dating of infection is mandatory to
prevent complications. T.gondii IgM persists in serum for
months after infection, hence, not suitable as an evidence
of recent infection, beside its lack of speciﬁcity. T.gondii
IgG avidity assay is expected to distinguish recent and past
infection. High avidity excludes recent infection in the pre-
ceding 16—20 weeks, while low avidity doesn’t differentiate
recent from old infection. This study evaluated the use of
IgG-avidity assay and IgG and IgM to detect recent toxoplas-
mosis in early pregnancy.
Methods: Sera from 2070 asymptomatic Saudi Arabian
pregnant women at different gestational stages were ﬁrst
screened for T.gondii IgG by indirect hemagglutination test
(Toxocell IHA, biokit, Spain). Enzyme linked ﬂuorescent
assay (ELFA, VIDAS, BioMerieux, France) was used to detect
T.gondii IgM and to measure total IgG and IgG-avidity index
(AI).
Results: Out of 401 IHA-positive sera, 151 (37.7%) sam-
ples were positive for T.gondii IgM, among which AI was
low in 17 samples (11.3%), intermediate in 1 (0.6%), and
high in 133 samples (88.1%). The possibility of recent infec-
tion in IgM-positive sera was excluded with a high IgG AI
(95% CI, 83—93%). High AI was shown in 97.8% of IgM-
negative sera. These ﬁnding minimized the value of a
positive IgM ﬁnding as single indicator for acute recent infec-
tion. Actually, it highlighted the value of IgG avidity assay to
exclude recent infection. No signiﬁcant correlation between
level of IgG, and presence of either low or high AI; or
between IgG level and presence of IgM in serum (r≈ 0.092)
(p < 0.05.).
Conclusion: For early diagnosis of T. gondii infection,
pregnant women should be initially screened for IgG, to
determine the patient’s immune status; followed by IgM
assay of IgG-positive sera. Absence of serum IgM excludes
